Loading...
Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
BACKGROUND: The advent of targeted therapy for cancer treatment has brought about a paradigm shift in the clinical management of human malignancies. Agents such as erlotinib used for EGFR-mutant non-small cell lung cancer or imatinib for chronic myeloid leukemia, for instance, lead to rapid tumor re...
Na minha lista:
| Udgivet i: | PLoS One |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4633116/ https://ncbi.nlm.nih.gov/pubmed/26536620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0141665 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|